ArticleMolecular and cellular biology1998
Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage.
Article in Molecular and cellular biology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 86 citations in OpenAlex.
- Article
- The (Lack of) DNA Double-Strand Break Repair Pathway Choice During V(D)J Recombination.Frontiers in genetics · 2021Review
- Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers.Trends in cancer · 2020Review
- Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells.Scientific reports · 2018Article
- Article
- Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.Molecular cancer research : MCR · 2014Article
- De novo-generated small palindromes are characteristic of amplicon boundary junction of double minutes.International journal of cancer · 2013Article
- N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy.Oncogene · 2013Article
- Geminin functions downstream of p53 in K-ras-induced gene amplification of dihydrofolate reductase.Cancer research · 2012Article
- CREG1 enhances p16(INK4a) -induced cellular senescence.Cell cycle (Georgetown, Tex.) · 2011Article
- Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene.Oncogene · 2009Article
- Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis.Genes & development · 2007Article
- Nucleotide excision repair in an immunoglobulin variable gene is less efficient than in a housekeeping gene.Molecular immunology · 2007Article
- Intrastrand annealing leads to the formation of a large DNA palindrome and determines the boundaries of genomic amplification in human cancer.Molecular and cellular biology · 2007Article
- Genome position and gene amplification.Genome biology · 2007Article
- Disparate contributions of the Fanconi anemia pathway and homologous recombination in preventing spontaneous mutagenesis.Nucleic acids research · 2007Article
- A mechanism of palindromic gene amplification in Saccharomyces cerevisiae.Genes & development · 2005Article
- Structure of a palindromic amplicon junction implicates microhomology-mediated end joining as a mechanism of sister chromatid fusion during gene amplification.Nucleic acids research · 2004Article
- Murine pancreatic tumor cell line TD2 bears the characteristic pattern of genetic changes with two independently amplified gene loci.Oncogene · 2003Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amplification of genes involved in signal transduction and cell cycle control occurs in a significant fraction of human cancers. Loss of p53 function has been proposed to enable cells with gene amplification to arise spontaneously during growth in vitro. However, this conclusion derives from studies employing the UMP synthesis inhibitor N-phosphonacetyl-L-aspartate (PALA), which, in addition to selecting for cells containing extra copies of the CAD locus, enables p53-deficient cells to enter S phase and acquire the DNA breaks that initiate the amplification process. Thus, it has not been possible to determine if gene amplification occurs spontaneously or results from the inductive effects of the selective agent. The studies reported here assess whether p53 deficiency leads to spontaneous genetic instability by comparing cell cycle responses and amplification frequencies of the human fibrosarcoma cell line HT1080 when treated with PALA or with methotrexate, an antifolate that, under the conditions used, should not generate DNA breaks. p53-deficient HT1080 cells generated PALA-resistant variants containing amplified CAD genes at a frequency of >10(-5). By contrast, methotrexate selection did not result in resistant cells at a detectable frequency (<10(-9)). However, growth of HT1080 cells under conditions that induced DNA breakage prior to selection generated methotrexate-resistant clones containing amplified dihydrofolate reductase sequences at a high frequency. These data demonstrate that, under standard growth conditions, p53 loss is not sufficient to enable cells to produce the DNA breaks that initiate amplification. We propose that p53-deficient cells must proceed through S phase under conditions that induce DNA breakage for genetic instability to occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.